Σχόλια > Εγκλημα στο χώρο της Υγείας

Επιστημονικές Ερευνες κατά της Χημειοθεραπείας

(1/3) > >>

Rose:
Περισσότεροι από 100 γιατροί, ασθενείς-επιζώντες, ερευνητές, και εξέχοντες επιστήμονες από 20 χώρες, ενώνουν δυνάμεις στην καλύτερη και πιο ολοκληρωμένη δουλειά που έγινε ποτέ για τον καρκίνο.

Η αληθινή ιστορία της χημειοθεραπείας και το φαρμακευτικό μονοπώλιο - Επεισόδιο 1
https://www.youtube.com/watch?v=Rc-O2pVQ2uU

Επεισόδιο 2 - Μαστός, Ορμόνες, Δερματικός, Επιγενετική Αιθέρια Έλαια
https://www.youtube.com/watch?v=i7qyX4Y0lIw

Επεισόδιο 3 - Αντικαρκινικοί Ιοί, Καρκινικά Βλαστοκύτταρα, Μεταλλαγμένα, Χυμοί
https://www.youtube.com/watch?v=wIzyRkqJJ64

Επεισόδιο 4 - Διεγερσιτοξίνες, το φαρμακείο της φύσης & θεραπεία με ήχο και φως
https://www.youtube.com/watch?v=o0hRmaNgwvg

Επεισόδιο 5 - Τυφλά σημεία του Καρκίνου, Τοξικά Εμβόλια, Ομοιοπαθητική, Συναισθήματα
https://www.youtube.com/watch?v=VavNbOZ-cac

Επεισόδιο 6 - Φαινόμενο NOCEBO, θεραπευτικά εμβόλια, προηγμένη αποτοξίνωση, Γερμανική κλίνική
https://www.youtube.com/watch?v=aT_mLj2WlCw

Επεισόδιο 7 - Η Καθαρή Ηλεκτρική ενέργεια, το μοναδικό Ύδωρ, το φυσικό φώς, συνδυασμένες υπερ-τροφές
https://www.youtube.com/watch?v=VZA2gmIH4wc

ΕΠΕΙΣΟΔΙΟ 8 - Η Κάνναβη, φυσικοί επιγενετικοί διακόπτες, τα πεπτίδια, μικροθρεπτικά συστατικά
https://www.youtube.com/watch?v=cL1NYl3nCYk

ΕΠΕΙΣΟΔΙΟ 9 - Οι νικητές του καρκίνου και οι ιστορίες επιτυχίας τους
https://www.youtube.com/watch?v=c_QK9qDe7b0

Ερωτήσεις - Απαντήσεις Μέρος 1/2 - "Η Αλήθεια για τον Καρκίνο, Μια Παγκόσμια Αναζήτηση"
https://www.youtube.com/watch?v=fYQnoCs73ak

Ερωτήσεις - Απαντήσεις Μέρος 2/2 - "Η Αλήθεια για τον Καρκίνο, Μια Παγκόσμια Αναζήτηση""
https://www.youtube.com/watch?v=i3WSWOKgn40

Rose:
https://www.cell.com/cancer-cell/fulltext/S1535-6108(11)00447-8

ARTICLE| VOLUME 21, ISSUE 1, P66-81, JANUARY 17, 2012
Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway
Vesselina G. Cooke 5
Valerie S. LeBleu 5
Doruk Keskin
Aline Damascena
Ricardo R. Brentani
Raghu Kalluri

Summary
The functional role of pericytes in cancer progression remains unknown. Clinical studies suggest that low numbers of vessel-associated pericytes correlated with a drop in overall survival of patients with invasive breast cancer. Using genetic mouse models or pharmacological inhibitors, pericyte depletion suppressed tumor growth but enhanced metastasis. Pericyte depletion was further associated with increased hypoxia, epithelial-to-mesenchymal transition (EMT), and Met receptor activation. Silencing of Twist or use of a Met inhibitor suppressed hypoxia and EMT/Met-driven metastasis. In addition, poor pericyte coverage coupled with high Met expression in cancer cells speculates the worst prognosis for patients with invasive breast cancer. Collectively, our study suggests that pericytes within the primary tumor microenvironment likely serve as important gatekeepers against cancer progression and metastasis.

Highlights
Pericyte loss increases tumor hypoxia, HIF1α and Met expression, EMT, and metastasis
Pharmacological targeting of pericytes or Met inhibits EMT and reduces metastasis
Reduced pericytes and Met overexpression correlate with poor patient prognosis
Cancer cell-autonomous program and stromal alterations combine to support metastasis

Significance
Pericyte coverage and its relation to metastasis are poorly understood. This study suggests that pericyte coverage on tumor vasculature serves as a key negative regulator of metastasis. Clinical studies suggest that cancer patients with low numbers of vessel-associated pericytes exhibit a high mortality rate. Cancer cell autonomous changes cooperate with stromal changes to determine the rate of cancer progression and metastasis.

Introduction
Metastasis is the leading cause of death in cancer patients. The formation of secondary tumors or metastasis is greatly influenced by multifaceted tumor-stroma interactions, in which stromal components of the tumor microenvironment can influence the behavior of the cancer cells (Coussens et al., 2000, Joyce, 2005, Thiery, 2009). While cancer cell-autonomous changes are undoubtedly critical for cancer progression and metastasis, the functional contribution of stromal cells is still emerging.
Pericytes are an integral component of the tissue vasculature. As perivascular stromal cells, pericytes provide structural support to blood vessels and regulate tissue physiology via its influence on vascular stability (Dore-Duffy and Cleary, 2011, Kim et al., 2006). Due to their essential function in vascular development, pericytes are also speculated to play an important role in tumor angiogenesis. Angiogenesis is required for the growth of tumors, and VEGF-mediated proliferation and migration of endothelial cells is critical for the generation of new capillaries, which is further supported by the recruitment of pericytes (Raza et al., 2010). Some studies have explored strategies that target both endothelial cells and pericytes (Bergers et al., 2003, Lu et al., 2007) or pericytes alone (Lu et al., 2007, Ozerdem, 2006a) to inhibit tumor angiogenesis and tumor growth. However, clinical data correlates low pericyte coverage with poor patient prognosis (O'Keeffe et al., 2008, Stefansson et al., 2006, Yonenaga et al., 2005), and disruption of pericytes has also been suggested to enhance metastasis (Xian et al., 2006).
The growth of tumors is often associated with defective tumor vasculature that cannot keep up with the overall oxygen and metabolic needs, ultimately resulting in tumor hypoxia (Harris, 2002, Semenza, 2003). Diminished oxygen levels lead to the activation and stabilization of the transcription factor HIF1α (Pouysségur et al., 2006), and hypoxia and HIF1α expression are correlated with poor prognosis and metastasis in cancer patients (Birner et al., 2000, Bos et al., 2003, Brizel et al., 1997, Vleugel et al., 2005). Hypoxia induces epithelial-to-mesenchymal transition (EMT) of cells specifically via HIF1α activation of the master regulator of EMT Twist (Sun et al., 2009, Yang et al., 2008), which is suggested to play an essential role in promoting metastasis (Yang et al., 2004).
Met, the receptor for hepatocyte growth factor (HGF), is also a key promoter of EMT (Birchmeier et al., 2003). Furthermore, the Met promoter contains HIF1α binding sites and is regulated by both hypoxia and HIF1α (Hara et al., 2006, Hayashi et al., 2005, Pennacchietti et al., 2003). HGF/Met expression is also upregulated in many cancers (Di Renzo et al., 1991), correlating with disease progression and metastasis (Di Renzo et al., 1995, Kenworthy et al., 1992) (Natali et al., 1993).

Using genetically engineered mouse models (GEMMs) and pharmacological targeting of pericytes, we examined whether pericyte deficiency positively or negatively affects metastasis and explored possible underlying mechanisms.

Rose:
SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment

https://www.nature.com/articles/onc2015494

SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment
Y Sun, D Zhu, F Chen, M Qian, H Wei, W Chen & J Xu

Abstract
Most tumors initially respond to cytotoxic treatments, but acquired resistance often follows. The tumor microenvironment (TME) is a major barrier to clinical success by compromising therapeutic efficacy, and pathological relevance of multiple soluble factors released by a therapeutically remodeled TME remains largely unexplored. Here we show that the secreted frizzled-related protein 2 (SFRP2), a Wnt pathway modulator, is produced by human primary fibroblasts after genotoxic treatments. SFRP2 induction is remarkable in tumor stroma, with transcription mainly modulated by the nuclear factor-κB (NF-κB) complex, a property shared by several effectors of the DNA damage secretory program. Instead of directly altering canonical Wnt signaling, SFRP2 augments β-catenin activities initiated by WNT16B, another soluble factor from DNA-damaged stroma. WNT16B recognizes cancer cell surface receptors including frizzled (FZD) 3/4/6, a process enhanced by SFRP2, coordinated by the co-receptor LRP6 but subject to abrogation by DKK1. Importantly, we found WNT16B plays a central role in promoting advanced malignancies particularly acquired resistance by counteracting cell death, an effect that can be minimized by a neutralizing antibody co-administered with classical chemotherapy. Furthermore, DNA damage-triggered expression of WNT16B is systemic, imaged by significant induction among diverse solid organs and circulation in peripheral blood, thereby holding promise as not only a TME-derived anticancer target but also a novel biomarker for clinical evaluation of treatment efficacy. Overall, our study substantiates the biological complexity and pathological implication of a therapy-activated TME, and provides the proof of principle of co-targeting tumor and the TME to prevent acquired resistance, with the aim of improving intervention outcome in an era of precision medicine

Rose:
https://naturalsociety.com/chemotherapy-makes-cancer-far-worse/

Woops! Study Accidentally Finds Chemotherapy Makes Cancer Far Worse

By Natural Society
Posted On August 7, 2012

A team of researchers looking into why cancer cells are so resilient accidentally stumbled upon a far more important discovery. While conducting their research, the team discovered that chemotherapy actually heavily damages healthy cells and subsequently triggers them to release a protein that sustains and fuels tumor growth. Beyond that, it even makes the tumor highly resistant to future treatment.

Reporting their findings in the journal Nature Medicine, the scientists report that the findings were ‘completely unexpected’. Finding evidence of significant DNA damage when examining the effects of chemotherapy on tissue derived from men with prostate cancer, the writings are a big slap in the face to mainstream medical organizations who have been pushing chemotherapy as the only option to cancer patients for years.


 
The news comes after it was previously ousted by similarly-breaking research that expensive cancer drugs not only fail to treat tumors, but actually make them far worse. The cancer drugs were found to make tumors ‘metasize’ and grow massively in size after consumption. As a result, the drugs killed the patients more quickly.

Known as WNT16B, scientists who performed the research say that this protein created from chemo treatment boosts cancer cell survival and is the reason that chemotherapy actually ends lives more quickly. Co-author Peter Nelson of the Fred Hutchinson Cancer Research Center in Seattle explains:

“WNT16B, when secreted, would interact with nearby tumour cells and cause them to grow, invade, and importantly, resist subsequent therapy.”

The team then complimented the statement with a word of their own:

“Our results indicate that damage responses in benign cells… may directly contribute to enhanced tumour growth kinetics.”

Meanwhile, dirt cheap substances like turmeric and ginger have consistently been found to effectively shrink tumors and combat the spread of cancer. In a review of 11 studies, it was found that turmeric use reduced brain tumor size by a shocking 81%. Further research has also shown that turmeric is capable of halting cancer cell growth altogether. One woman recently hit the mainstream headlines by revealing her victory against cancer with the principal spice used being turmeric.

This accidental finding reached by scientists further shows the lack of real science behind many ‘old paradigm’ treatments, despite what many health officials would like you to believe. The truth of the matter is that natural alternatives do not even receive nearly as much funding as pharmaceutical drugs and medical interventions because there’s simply no room for profit. If everyone was using turmeric and vitamin D for cancer (better yet cancer prevention), major drug companies would lose out.

Rose:
H ΚΕΡΔΟΦΟΡΑ ΜΑΦΙΑ ΤΟΥ ΚΑΡΚΙΝΟΥ ΜΕ ΛΑΘΟΣ ΔΙΑΓΝΩΣΕΙΣ
https://www.triklopodia.gr/h-%CE%BA%CE%B5%CF%81%CE%B4%CE%BF%CF%86%CE%BF%CF%81%CE%B1-%CE%BC%CE%B1%CF%86%CE%B9%CE%B1-%CF%84%CE%BF%CF%85-%CE%BA%CE%B1%CF%81%CE%BA%CE%B9%CE%BD%CE%BF%CF%85-%CE%BC%CE%B5-%CE%BB%CE%B1%CE%B8%CE%BF%CF%83/?fbclid=IwAR1VQnU9sbEutbXbOa43qwWQH_e1wonhs1L579waoAMD9HYcGnHRnYhi6_Y

Γράφει η Σουλτάνα Χειλαδάκη

Κάθε χρόνο ένα κύκλωμα μαφίας, με ένα τζίρο δισεκατομμυρίων, σε συνεργασία με εντεταλμένα εργαστήρια που βγάζουν σκόπιμα διαγνώσεις για καρκίνο σε ανύποπτους ασθενείς, κάνει θραύση σε πολλές δυτικές χώρες. Η διαφθορά των ιατρικών και εργαστηριακών κυκλωμάτων είναι εμφανής σε όλα τα επίπεδα. Ποιος θα μπορούσε να σκεφτεί ότι θα φτάσουμε στο σημείο, ιατροί να γνωματεύουν λάθος διαγνώσεις για καρκίνο σε υγιείς εξεταζομένους για να κερδίσουν χρήματα.

Και όμως αυτό συμβαίνει πιο συχνά από ότι μπορούμε να φανταστούμε. Όλο αυτό το κύκλωμα μπορεί να αποκαλυφτεί μόνο στην περίπτωση που ένας ιατρός αποδειχτεί επ αυτοφώρω ότι έχει κάνει σκόπιμα λάθος διάγνωση. Είναι πράγματι μια μεγάλη αθλιότητα που δυστυχώς αμαυρώνει το κύρος του ιατρικού κόσμου, δηλαδή ιατροί να φορτώνουν με ανύπαρκτο καρκίνο τους εξεταζόμενους προκειμένου να κερδίζουν χρήματα από τις χημειοθεραπείες τους.

Πλοήγηση

[0] Λίστα μηνυμάτων

[#] Επόμενη σελίδα